Bleb-related infection associated with an intraluminal stent suture after PreserFlo MicroShunt implantation: a case report Authors: Masashi Nishigaki, Atsuya Miki, Chiaki Nogawa, Taro Muroya, Motohiro Kamei Published: 2026 ABSTRACT AbstractPurposeThe PreserFlo MicroShunt (PMS) is a glaucoma drainage device designed to reduce intraocular pressure (IOP) with fewer complications than conventional filtering surgery. An intraluminal stent suture can prevent early postoperative hypotony; however, a potential infection risk exists. We report a rare case of bleb-related infection associated with an intraluminal stent suture in the PMS.ObservationAn 80-year-old man with secondary glaucoma due to bilateral cytomegalovirus anterior uveitis underwent bilateral PMS implantation with a 10-0 nylon intraluminal stent suture. The stent was removed from the right eye 1 month postoperatively but retained in the left eye because the IOP remained stable. At 3.5 months postoperatively, the left eye developed eyelid swelling, ocular pain, conjunctival hyperemia, and anterior chamber inflammation without bleb leakage. Infection related to the stent suture was suspected. After stent removal, suture culture grew Streptococcus agalactiae. Intensive topical and intracameral antibiotic therapy resolved the inflammation within 2 weeks. Transient hypotony and choroidal detachment occurred after removal but resolved conservatively, and the IOP stabilized.Conclusion and importanceIntraluminal stent sutures may effectively prevent early postoperative hypotony after PMS implantation, but their indication should be carefully considered while balancing the risks of hypotony and infection. Early stent removal and careful postoperative monitoring are essential.Keywords: PreserFlo MicroShunt, Minimally invasive glaucoma surgery, Bleb-related infection, Intraluminal stent suture, Postoperative hypotony Introduction The PreserFlo MicroShunt (PMS) (Santen Inc., Osaka, Japan) is a minimally invasive glaucoma drainage device that facilitates aqueous humor outflow from the anterior chamber to the subconjunctival or sub-Tenon's space. The microshunt, comprised of poly(styrene-block-isobutylene-block-styrene), an inert and biocompatible material, is 8.5 mm long with a 70-μm lumen diameter. Unlike conventional filtering surgeries, PMS implantation does not require creation of a scleral flap, sclerostomy, or peripheral iridectomy, which is thought to reduce postoperative inflammation and complications. Postoperative hypotony-related complications are less frequent with the PMS compared with trabeculectomy.1 Nevertheless, postoperative hypotony still can occur after PMS implantation. Early postoperative hypotony has been reported more frequently compared to trabeculectomy.2 Preoperative high intraocular pressure (IOP) and a high preoperative medication score are risk factors for hypotension after PMS.3 Additionally, secondary glaucoma is a risk factor for hypotony after trabeculectomy.4 To prevent early postoperative hypotony, several techniques have been reported, including the insertion of a stent suture into the lumen of the microshunt.3,5,6 Among these, Gehrke et al.6 described a technique using 10-0 nylon sutures, in which, following placement of the PMS in the anterior chamber, the stent suture is introduced from the distal end of the tube into the anterior chamber. The external end of the suture is embedded in the corneal stroma near the limbus for later removal using forceps. We report a rare case of bleb-related infection associated with a stent suture placed inside the PMS. Case report An 80-year-old man presented with elevated IOP and decreased best-corrected visual acuity (BCVA) bilaterally due to secondary glaucoma after bilateral cytomegalovirus anterior uveitis. He had experienced previous recurrent episodes of iritis and IOP elevation. At presentation, the anterior uveitis was inactive, but the IOP remained elevated. At the initial visit, the patient was using four topical antiglaucoma medications, topical ganciclovir eye drops, and oral acetazolamide, with an IOP of 22 mmHg. The BCVA was 1.0 in the right eye and 0.01 in the left eye. Goldmann perimetry revealed right temporal hemianopia attributable to a previous cerebral infarction, while the left eye had advanced glaucomatous visual field loss with disappearance of the central field. Because of severe visual field damage and inadequate IOP control despite maximal medical therapy, bilateral PMS implantation was planned. Under local anesthesia, bilateral PMS implantation was performed according to the standard surgical protocol. Briefly, 0.04% mitomycin C was injected into the sub-Tenon's space and allowed to remain for 3 minutes, after which a limbal conjunctival incision was made and the sub-Tenon's space was thoroughly irrigated with 150 mL of balanced salt solution. The PMS was inserted into the anterior chamber about 3 mm posterior to the limbus, and aqueous humor outflow from the distal end was confirmed. Because the risk of postoperative hypotony is higher in cases with uveitic glaucoma, a 10-0 nylon suture was inserted into the microshunt lumen to reduce the risk of postoperative hypotony. One end of the nylon suture was advanced into the anterior chamber through the microshunt lumen, while the other end was embedded in the corneal stroma (Fig. 1). The conjunctiva was closed with 10-0 nylon sutures. The surgery was completed without complications. Intraoperative image. A 10-0 nylon suture is inserted into the PMS as a stent. One end of the nylon suture is partially embedded in the cornea. The image on the right shows the nylon thread embedded in the cornea (dotted line). Postoperatively, topical gatifloxacin eye drops were administered four times daily and topical betamethasone six times daily. One week postoperatively, the IOP was 8 mmHg bilaterally with the intraluminal stents in place. At 2 weeks, the IOP increased to 13 mmHg bilaterally. At 4 weeks, the BCVA was 0.7 in the right eye and 0.01 in the left eye, with IOPs of 15 and 13 mmHg, respectively. Therefore, the right stent was removed, whereas the left was retained. One week later, the right IOP decreased to 5 mmHg and mild choroidal folds, and topical atropine was added once daily. Because hypotony developed after the right stent was removed, the left stent was retained. Gatifloxacin was discontinued, and topical betamethasone was reduced to twice daily. At 1.5 months, the right choroidal folds resolved, and atropine was discontinued. At 3 months, the IOP was 5 mmHg in the right eye and 12 mmHg in the left eye. Although the left bleb appeared ischemic, the IOP remained well controlled, and the left stent was left in place. At 3.5 months postoperatively, eyelid swelling and ocular pain in the left eye developed. Slit-lamp biomicroscopic showed discharge, conjunctival hyperemia, and inflammatory cells in the anterior chamber (Fig. 2). The Seidel test was negative. A bleb-related infection associated with the stent suture was suspected. The stent suture was removed immediately, and intracameral injections of vancomycin and ceftazidime were administered. The removed stent suture and aqueous humor samples were submitted for bacterial culture. Slit-lamp photograph obtained at 3.5 months postoperatively. (A) Eyelid swelling(arrow), conjunctival congestion, and eye discharge(circle). A 10-0 nylon suture is inserted into the anterior chamber from the PMS as a stent(arrow head). (B) Ischemic bleb and congestion. (C) Inflammatory cells in the anterior chamber(white circle). Topical levofloxacin and cefmenoxime eye drops were initiated hourly, along with ofloxacin ophthalmic ointment at bedtime. The following day, the anterior chamber inflammation had improved markedly; however, the IOP decreased to 6 mmHg due to stent removal, and choroidal detachment developed. Although bacterial culture of the aqueous humor was negative, bacterial culture of the removed stent suture yielded Streptococcus agalactiae. By day 4 after treatment initiation, inflammatory findings had nearly resolved, and topical antibiotics were reduced to six times daily. On day 7, antibiotic susceptibility testing confirmed that S. agalactiae was susceptible to levofloxacin, and cefmenoxime was therefore discontinued. Inflammation resolved almost completely within about 2 weeks after treatment initiation. The IOP gradually increased, reaching 15 mmHg about 1 month later, and the choroidal detachment resolved. Although bleb hyperemia improved, mild residual hyperemia persisted; therefore, topical gatifloxacin and fluorometholone were continued with a plan for gradual tapering. Throughout the clinical course, there was no decrease in VA, no intraocular extension of the infection, and no serious complications. Discussion This case involved bleb infection following PMS implantation in an eye with a retained intraluminal stent suture. The use of an intraluminal stent suture to prevent postoperative hypotony after PMS implantation has been described in several reports.3,5,6 Because one end of the stent is inserted into the anterior chamber and the other end is left extraocularly for later removal, an inherent risk of infection exists. Three possible mechanisms were considered to explain the development of blebitis in this case: recurrent CMV anterior uveitis, bleb infection arising independently from the ischemic bleb, and an infection associated with the retained intraluminal stent suture. Regarding the first possibility, recurrent CMV anterior uveitis could not be excluded because polymerase chain reaction (PCR) analysis of the aqueous humor was not performed. However, the aqueous humor culture was negative, and the anterior chamber inflammation and conjunctival hyperemia resolved with intensive antibiotic therapy alone, without additional anti-CMV treatment. These findings support bacterial infection rather than recurrent CMV anterior uveitis. The second and third possibilities concern the route of bacterial infection. Generally, bleb leakage has been reported as the greatest risk factor for bleb infection.7 However, in the current case, no obvious bleb leakage was observed at the time of infection. However, a stent suture was present, with one end in the anterior chamber and the other placed subconjunctivally, a portion of which was exposed on the corneal surface to facilitate removal. This suggests that the bleb-related infection likely developed through the intraluminal stent suture. Although the possibility that the infection arose independently from the ischemic bleb cannot be excluded, the positive bacterial culture obtained from the removed stent suture, together with the negative aqueous humor culture, suggested that the retained intraluminal stent suture was the most likely source of bacterial infection in this case. To minimize infection risk, we adopted the technique described by Lüke et al., in which the external portion of the stent suture is embedded in the corneal stroma.5 Despite this precaution, infection still occurred in the current case. The likely contributing factor was the prolonged stent retention. Although the exact timing of stent removal varies among reports, stent sutures are generally intended to be removed once the risk of hypotony has subsided. In this case, because the IOP remained 12 mmHg at 3 months postoperatively, the stent was not removed, resulting in extended retention. Prolonged retention inevitably increases the risk of infection. In addition, postoperative topical antibiotics were discontinued 1 month postoperatively. It has been reported that conjunctival sac bacterial flora increases with age.8 In this elderly patient, only topical dexamethasone was continued after discontinuation of antibiotics, potentially increasing the susceptibility to infection. Two potential strategies may reduce the risk of stent-related infection. The first is continuation of topical antibiotic therapy for as long as the stent remains in place. Although antibiotic and steroid drops are typically tapered over time, antibiotics would not be discontinued completely. However, long-term antibiotic use raises concerns about the development of resistant organisms and does not eliminate the risk of infection.9 The second strategy is elimination of the external exposure of the stent by cutting the extraocular portion or burying it beneath the conjunctiva. This could substantially reduce the infection risk but would make later stent removal more difficult. If one end of the stent remains in the anterior chamber, removal from the anterior chamber side is possible, although this carries its own risk of infection during the procedure. Fundamentally, the insertion of intraluminal stents carries a risk of blebitis and may even progress to endophthalmitis; therefore, its use should be restricted to patients at high risk of hypotony. Conclusion Placing an intraluminal stent suture in the PMS is an effective method for preventing early postoperative hypotony; however, it carries a risk of infection, as demonstrated in this case. Therefore, the indication for intraluminal stent suture placement should be carefully considered by balancing the risk of postoperative hypotony against potential complications, including infection. In cases with intraluminal stents, careful postoperative monitoring and appropriate infection prevention strategies are required, and the intraluminal stent suture should be removed as soon as feasible. CRediT authorship contribution statement Masashi Nishigaki: Writing – review & editing, Writing – original draft, Visualization, Validation, Software, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Atsuya Miki: Writing – review & editing, Writing – original draft, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Chiaki Nogawa: Writing – review & editing, Investigation. Taro Muroya: Writing – review & editing, Investigation, Data curation. Motohiro Kamei: Writing – review & editing, Supervision, Investigation, Conceptualization. Patient consent Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Declaration of generative AI and AI-assisted technologies in the manuscript preparation process During the preparation of this work, the authors used GEMINI only for checking the grammatical errors. After using this tool, the authors reviewed the content and take full responsibility for the content of the article. Financial support This work was supported by JSPS KAKENHI Grant Number 25K12844. Atsuya Miki reports financial support was provided by Japan Society for the Promotion of Science. Atsuya Miki reports a relationship with Santen Pharmaceutical Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Menicon Co Ltd that includes: funding grants. Atsuya Miki reports a relationship with Rohto Nitten that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Novartis that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Alcon Japan Ltd that includes: speaking and lecture fees. Atsuya Miki reports arelationship with Senju Pharmaceutical Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Kowa Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Otsuka Pharmaceutical Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Rohto Pharmaceutical Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Viatris Inc that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Lumibird that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Nitto Medic Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Topcon that includes: speaking and lecture fees. Atsuya Miki reports a relationship with SEED that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Chugai Pharmaceutical Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with HOYA that includes: speaking and lecture fees. Atsuya Miki reports a relationship with AMO Japan that includes: speaking and lecture fees. Motohiro Kamei reports a relationship with Alcon Japan Ltd that includes: consulting or advisory, funding grants, and speaking and lecture fees. Motohiro Kamei reports a relationship with Kowa Company Ltd that includes: speaking and lecture fees and travel reimbursement. Motohiro Kamei reports a relationship with Bayer Yakuhin, Ltd that includes: speaking and lecture fees. Motohiro Kamei reports a relationship with Otsuka Pharmaceutical Co Ltd that includes: funding grants and speaking and lecture fees. Motohiro Kamei reports a relationship with Chugai Pharmaceutical Co Ltd that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Motohiro Kamei reports a relationship with Santen Pharmaceutical Co Ltd that includes: speaking and lecture fees. Motohiro Kamei reports a relationship with Hoya Corporation that includes: funding grants and speaking and lecture fees. Motohiro Kamei reports a relationship with Senju Pharmaceutical Co Ltd that includes: consulting or advisory, funding grants, and speaking and lecture fees. Motohiro Kamei reports a relationship with Nidek Co Ltd that includes: speaking and lecture fees. Motohiro Kamei reports a relationship with Novartis Pharma k.K. that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Atsuya Miki reports financial support was provided by Japan Society for the Promotion of Science. Atsuya Miki reports a relationship with Santen Pharmaceutical Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Menicon Co Ltd that includes: funding grants. Atsuya Miki reports a relationship with Rohto Nitten that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Novartis that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Alcon Japan Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Senju Pharmaceutical Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Kowa Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Otsuka Pharmaceutical Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Rohto Pharmaceutical Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Viatris Inc that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Lumibird that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Nitto Medic Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Topcon that includes: speaking and lecture fees. Atsuya Miki reports a relationship with SEED that includes: speaking and lecture fees. Atsuya Miki reports a relationship with Chugai Pharmaceutical Co Ltd that includes: speaking and lecture fees. Atsuya Miki reports a relationship with HOYA that includes: speaking and lecture fees. Atsuya Miki reports a relationship with AMO Japan that includes: speaking and lecture fees. Motohiro Kamei reports a relationship with Alcon Japan Ltd that includes: consulting or advisory, funding grants, and speaking and lecture fees. Motohiro Kamei reports a relationship with Kowa Company Ltd that includes: speaking and lecture fees and travel reimbursement. Motohiro Kamei reports a relationship with Bayer Yakuhin, Ltd that includes: speaking and lecture fees. Motohiro Kamei reports a relationship with Otsuka Pharmaceutical Co Ltd that includes: funding grants and speaking and lecture fees. Motohiro Kamei reports a relationship with Chugai Pharmaceutical Co Ltd that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Motohiro Kamei reports a relationship with Santen Pharmaceutical Co Ltd that includes: speaking and lecture fees. Motohiro Kamei reports a relationship with Hoya Corporation that includes: funding grants and speaking and lecture fees. Motohiro Kamei reports a relationship with Senju Pharmaceutical Co Ltd that includes: consulting or advisory, funding grants, and speaking and lecture fees. Motohiro Kamei reports a relationship with Nidek Co Ltd that includes: speaking and lecture fees. Motohiro Kamei reports a relationship with Novartis Pharma k.K. that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements All authors contributed to patient management and writing of the report. References